134 related articles for article (PubMed ID: 14747443)
1. The immunohistochemical localisation of somatostatin receptors 1, 2, 3, and 5 in acoustic neuromas.
Stafford ND; Condon LT; Rogers MJ; Helboe L; Crooks DA; Atkin SL
J Clin Pathol; 2004 Feb; 57(2):168-71. PubMed ID: 14747443
[TBL] [Abstract][Full Text] [Related]
2. Expression of somatostatin receptor subtypes (SSTR1-5) in Alzheimer's disease brain: an immunohistochemical analysis.
Kumar U
Neuroscience; 2005; 134(2):525-38. PubMed ID: 15961235
[TBL] [Abstract][Full Text] [Related]
3. The expression of somatostatin receptors 3, 4 and 5 in laryngeal pathology.
Condon LT; Stafford ND; Bedford KJ; MacDonald AW; Atkin SL
Eur Arch Otorhinolaryngol; 2008 Jul; 265 Suppl 1():S63-7. PubMed ID: 18066572
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores.
Diakatou E; Alexandraki KI; Tsolakis AV; Kontogeorgos G; Chatzellis E; Leonti A; Kaltsas GA
Clin Endocrinol (Oxf); 2015 Sep; 83(3):420-8. PubMed ID: 25808161
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1--5 and correlation with receptor protein expression and tumor pathology.
Kumar U; Grigorakis SI; Watt HL; Sasi R; Snell L; Watson P; Chaudhari S
Breast Cancer Res Treat; 2005 Jul; 92(2):175-86. PubMed ID: 15986128
[TBL] [Abstract][Full Text] [Related]
6. The expression of somatostatin receptors 1 and 2 in benign, pre-malignant and malignant laryngeal lesions.
Stafford ND; Condon LT; Rogers MJ; MacDonald AW; Atkin SL
Clin Otolaryngol Allied Sci; 2003 Aug; 28(4):314-9. PubMed ID: 12871244
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas.
Bläker M; Schmitz M; Gocht A; Burghardt S; Schulz M; Bröring DC; Pace A; Greten H; De Weerth A
J Hepatol; 2004 Jul; 41(1):112-8. PubMed ID: 15246216
[TBL] [Abstract][Full Text] [Related]
8. Olfactory receptor 51E1 as a novel target for diagnosis in somatostatin receptor-negative lung carcinoids.
Giandomenico V; Cui T; Grimelius L; Öberg K; Pelosi G; Tsolakis AV
J Mol Endocrinol; 2013 Dec; 51(3):277-86. PubMed ID: 23969981
[TBL] [Abstract][Full Text] [Related]
9. Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung Carcinoids: Implications for a Therapeutic Role.
Kanakis G; Grimelius L; Spathis A; Tringidou R; Rassidakis GZ; Öberg K; Kaltsas G; Tsolakis AV
Neuroendocrinology; 2015; 101(3):211-22. PubMed ID: 25765100
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, and Biological Evaluation of
Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z
Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911
[TBL] [Abstract][Full Text] [Related]
11. Colocalization of somatostatin receptor subtypes (SSTR1-5) with somatostatin, NADPH-diaphorase (NADPH-d), and tyrosine hydroxylase in the rat hypothalamus.
Kumar U
J Comp Neurol; 2007 Sep; 504(2):185-205. PubMed ID: 17626271
[TBL] [Abstract][Full Text] [Related]
12. Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides.
Raynor K; Murphy WA; Coy DH; Taylor JE; Moreau JP; Yasuda K; Bell GI; Reisine T
Mol Pharmacol; 1993 Jun; 43(6):838-44. PubMed ID: 8100350
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility.
Nasir A; Stridsberg M; Strosberg J; Su PH; Livingston S; Malik HA; Kelley ST; Centeno BA; Coppola D; Malafa ME; Yeatman TJ; Kvols LK
Cancer Control; 2006 Jan; 13(1):52-60. PubMed ID: 16508627
[TBL] [Abstract][Full Text] [Related]
14. Expression of somatostatin receptor subtype 2 and subtype 5 in thyroid malignancies.
Woelfl S; Bogner S; Huber H; Salaheddin-Nassr S; Hatzl M; Decristoforo C; Virgolini I; Gabriel M
Nuklearmedizin; 2014; 53(5):179-85. PubMed ID: 24967740
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin and its receptor family.
Patel YC
Front Neuroendocrinol; 1999 Jul; 20(3):157-98. PubMed ID: 10433861
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal stromal tumors (GISTs) express somatostatin receptors and bind radiolabeled somatostatin analogs.
Arne G; Nilsson B; Dalmo J; Kristiansson E; Arvidsson Y; Forssell-Aronsson E; Nilsson O; Ahlman H
Acta Oncol; 2013 May; 52(4):783-92. PubMed ID: 23116418
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptor subtype 1 might be a predictor of better response to therapy in medullary thyroid carcinoma.
Kendler DB; Araújo ML; Alencar R; de Souza Accioly MT; Bulzico DA; de Noronha Pessoa CC; Accioly FA; de Farias TP; Lopes FPPL; Corbo R; Vaisman M; Vaisman F
Endocrine; 2017 Dec; 58(3):474-480. PubMed ID: 28948577
[TBL] [Abstract][Full Text] [Related]
18. SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary.
Lee M; Lupp A; Mendoza N; Martin N; Beschorner R; Honegger J; Schlegel J; Shively T; Pulz E; Schulz S; Roncaroli F; Pellegata NS
Endocr Relat Cancer; 2015 Feb; 22(1):111-9. PubMed ID: 25515731
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor gene expression in human ocular tissues: RT-PCR and immunohistochemical study.
Klisovic DD; O'Dorisio MS; Katz SE; Sall JW; Balster D; O'Dorisio TM; Craig E; Lubow M
Invest Ophthalmol Vis Sci; 2001 Sep; 42(10):2193-201. PubMed ID: 11527930
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies.
Lambertini C; Barzaghi-Rinaudo P; D'Amato L; Schulz S; Nuciforo P; Schmid HA
Regul Pept; 2013 Nov; 187():35-41. PubMed ID: 24188818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
